Safety of oral robenacoxib in the cat
- 8 July 2011
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 35 (3) , 290-300
Abstract
King, J. N., Hotz, R., Reagan, E. L., Roth, D. R., Seewald, W., Lees, P. Safety of oral robenacoxib in the cat. J. vet. Pharmacol. Therap. 35, 290–300.The safety of robenacoxib, a nonsteroidal anti‐inflammatory drug with high selectivity for inhibition of the cyclooxygenase (COX)‐2 isoform of COX, was investigated in the cat in two randomized, blinded, placebo‐controlled, parallel‐group studies. Robenacoxib was administered orally to healthy young domestic short‐hair cats at dosages of 0 (placebo), 5 and 10 mg/kg once daily for 28 days (study 1) and at 0 (placebo), 2, 6 and 10 mg/kg twice daily for 42 days (study 2). The recommended minimum dosage for robenacoxib tablets in cats is 1 mg/kg once daily (range 1–2.4 mg/kg). Relative to placebo treatment, no toxicologically significant effects of robenacoxib were recorded in either study, based on general observations of health, haematological and clinical chemistry variables and urinalyses in life, and by post mortem organ weight, gross pathology and histopathology assessments. Pharmacokinetic–pharmacodynamic simulations indicated that all dosages of robenacoxib were associated with marked inhibition of COX‐2 at peak effect (median Imax 97.8–99.4% inhibition) with lesser inhibition of COX‐1 (median Imax 26.8–58.3% inhibition). Inhibition of the COXs was short lasting, with >10% median inhibition persisting for 4.0 h for COX‐2 and 1.5 h for COX‐1. These levels of inhibition of COX‐1 and COX‐2 twice daily with robenacoxib were not associated with any detectable toxicity, suggesting that, as previously described in dogs, the high safety index of robenacoxib in cats may be related to a combination of its high COX‐2 selectivity and short residence time in the central compartment.Keywords
This publication has 22 references indexed in Scilit:
- Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2Journal of Veterinary Pharmacology and Therapeutics, 2011
- In vitroandex vivoinhibition of COX isoforms by robenacoxib in the cat: a comparative studyJournal of Veterinary Pharmacology and Therapeutics, 2010
- The pharmacokinetics of mavacoxib, a long‐acting COX‐2 inhibitor, in young adult laboratory dogsJournal of Veterinary Pharmacology and Therapeutics, 2010
- In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: A comparative studyResearch in Veterinary Science, 2010
- Safety and tolerability of 3-week and 6-month dosing of Deramaxx®(Deracoxib) chewable tablets in dogsJournal of Veterinary Pharmacology and Therapeutics, 2009
- Analytical determination and pharmacokinetics of robenacoxib in the dogJournal of Veterinary Pharmacology and Therapeutics, 2009
- Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxibJournal of Veterinary Pharmacology and Therapeutics, 2009
- Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX‐2 selective drug robenacoxibJournal of Veterinary Pharmacology and Therapeutics, 2009
- Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase‐2Journal of Veterinary Pharmacology and Therapeutics, 2009
- Nonsteroidal anti-inflammatory drugs in cats: a reviewVeterinary Anaesthesia and Analgesia, 2007